Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

MIRIA Development of Antimicrobial, Antiviral, and Antifungal Nanocoatings for Everyday Surfaces

Coordinator
Rina Consulting - Centro Sviluppo Materiali SpA, Italy
Runs
1 June 2022 to 31 May 2026
Status
Running
EU funding
€5.8m
Total cost
€5.8m
Partners
15 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101058751

What the project is doing

In the project's own words, from its summary on CORDIS.

Since the end of 2019, the spread of COVID has deeply changed our lifestyle, resulting in historical events and decisions, such as the EU block of non-essential travel among countries (COMM (2020) 499), affecting the whole EU society economically and psychologically. However, as reported in the HERA target priorities, the persistence of the emergency status requires daily actions that tackle the spread of COVID.In this economical, societal and clinical context, the project MIRIA aims to develop wide-range-antimicrobial nanocoatings to be used in hospitals and other environments where cross-contamination and contagion risk are significant issues.

In the wake of the covid outbreak, there has been large concern about infection spread of pathogens (i.e., bacteria, fungi, virus, and specifically SARS-CoV-2) via high traffic surfaces (i.e., medical equipment). State of the art and commercial products coating solutions that both target a range of mixed pathogens and different surfaces (e.g., glass, metal, textile) are unfortunately scant. MIRIA solutions aim to fill this void, impacting on EU health, both directly (by creating public safe environments) and indirectly (by reducing COVID spreading and decreasing ill-related work absences and psychological pathologies).

A reduction of the work absence of at least 5% with respect to the 2020 value (15M in EU) is expected. MIRIA main challenging ambition is to develop nanocoatings with a 99.99% effectiveness against a wide range of pathogens, especially SARS-CoV-2. This will be based on a four pieces puzzle: the knowledge in anti-microbial materials, nanopowders, nanocoating and pilot plant conduction. These nanocoatings will be brought to pilot scale (TRL6) and, within 3 years after the end of the project, they are foreseen to enter the market (TRL9).

The exploitation of MIRIA outputs deeply involves SMEs and the dissemination plan will follow a spill-over strategy in order to involve public and private stakeholders.

Topics

Who is involved

OrganisationCityCountryRole
Rina Consulting - Centro Sviluppo Materiali SpARomaItalyCoordinator
Univerzita KarlovaPraha 1CzechiaParticipant
Sud-Metall Beschlage GmbHAinringGermanyParticipant
Idener Research & Development AieSevillaSpainParticipant
Millidyne OyTampereFinlandParticipant
Teknologian Tutkimuskeskus VTT OyEspooFinlandParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Commissariat a L Energie Atomique Et Aux Energies AlternativesParisFranceParticipant
Consorzio Interuniversitario Nazionale per La Scienza E Tecnologia Dei MaterialiFirenzeItalyParticipant
Protec Surface Technologies SRLBedizzoleItalyParticipant
Takis SRLRomaItalyParticipant
Alvo Medical Spolka Z Ograniczona OdpowiedzialnosciaSmigielPolandParticipant
Helioenergia Spolka Z Ograniczona OdpowiedzialnosciaCzerwionka-LeszczynyPolandParticipant
Siec Badawcza Lukasiewicz - Instytut Metali NiezelaznychGliwicePolandParticipant
Cellcomb ABSaffleSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI